Zoledronic acid as adjuvant therapy in neovascular age-related macular degeneration: a randomised controlled pilot study
Aims To assess the feasibility of a study protocol for a randomised controlled trial of zoledronic acid (ZA) as adjuvant therapy for neovascular age-related macular degeneration (nAMD).Methods In this 1-year, randomised, double-blinded, placebo-controlled pilot study, nAMD patients were allocated 1:...
Saved in:
Main Authors: | Øystein Kalsnes Jørstad, Morten Carstens Moe, Morten Wang Fagerland, Yngvil Solheim Husum, Erik Fink Eriksen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-12-01
|
Series: | BMJ Open Ophthalmology |
Online Access: | https://bmjophth.bmj.com/content/9/1/e001964.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of optical coherence tomography vs. fluorescein angiography-based macular neovascularization classifications in age-related macular degeneration
by: Gábor G. Deák, et al.
Published: (2025-02-01) -
Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis
by: Francisco Rodríguez, et al.
Published: (2024-05-01) -
Predictive value of different baseline optical coherence tomography biomarkers for visual acuity changes in neovascular age-related macular degeneration
by: Hamid Riazi-Esfahani, et al.
Published: (2025-02-01) -
Neovascular age-related macular degeneration: disease pathogenesis and current state of molecular biomarkers predicting treatment response—a scoping review
by: Nikolaos Dervenis, et al.
Published: (2024-05-01) -
Saffron therapy for the ongoing treatment of age-related macular degeneration
by: Peter J McCluskey, et al.
Published: (2024-07-01)